Edwards Lifesciences Corp (NYSE:EW) hit a new 52-week high during trading on Monday . The company traded as high as $165.97 and last traded at $164.98, with a volume of 115074 shares. The stock had previously closed at $159.05.

A number of equities research analysts have commented on the company. Zacks Investment Research lowered Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Monday, July 16th. Citigroup raised their price objective on Edwards Lifesciences from $115.00 to $118.00 and gave the stock a “sell” rating in a research report on Tuesday, July 31st. ValuEngine upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating in a research report on Wednesday, September 19th. SunTrust Banks decreased their price objective on Edwards Lifesciences to $170.00 and set a “buy” rating for the company in a research report on Friday, August 10th. Finally, Raymond James assumed coverage on Edwards Lifesciences in a research report on Thursday, May 31st. They set an “outperform” rating and a $152.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and fifteen have issued a buy rating to the stock. Edwards Lifesciences has an average rating of “Buy” and a consensus price target of $152.45.

The company has a debt-to-equity ratio of 0.19, a current ratio of 1.86 and a quick ratio of 1.47. The company has a market capitalization of $32.18 billion, a price-to-earnings ratio of 44.30, a PEG ratio of 2.12 and a beta of 0.57.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, July 26th. The medical research company reported $1.24 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.13 by $0.11. Edwards Lifesciences had a return on equity of 29.11% and a net margin of 19.59%. The company had revenue of $972.00 million during the quarter, compared to the consensus estimate of $968.32 million. During the same period last year, the business earned $1.08 EPS. The business’s quarterly revenue was up 10.0% on a year-over-year basis. sell-side analysts predict that Edwards Lifesciences Corp will post 4.67 EPS for the current year.

In other news, CEO Michael A. Mussallem sold 32,900 shares of the firm’s stock in a transaction dated Tuesday, July 31st. The stock was sold at an average price of $141.86, for a total transaction of $4,667,194.00. Following the completion of the sale, the chief executive officer now directly owns 43,126 shares of the company’s stock, valued at approximately $6,117,854.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Scott B. Ullem sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, July 3rd. The stock was sold at an average price of $145.67, for a total value of $3,641,750.00. Following the sale, the chief financial officer now directly owns 41,265 shares of the company’s stock, valued at $6,011,072.55. The disclosure for this sale can be found here. Insiders have sold a total of 183,811 shares of company stock valued at $26,346,476 over the last ninety days. Company insiders own 1.84% of the company’s stock.

Several hedge funds have recently modified their holdings of EW. Private Capital Group LLC bought a new position in Edwards Lifesciences in the 2nd quarter worth approximately $112,000. Centaurus Financial Inc. bought a new position in Edwards Lifesciences in the 2nd quarter worth approximately $114,000. IHT Wealth Management LLC increased its position in Edwards Lifesciences by 84.6% in the 1st quarter. IHT Wealth Management LLC now owns 932 shares of the medical research company’s stock worth $126,000 after buying an additional 427 shares during the period. Signet Financial Management LLC bought a new position in Edwards Lifesciences in the 2nd quarter worth approximately $136,000. Finally, Ropes Wealth Advisors LLC increased its position in Edwards Lifesciences by 187.4% in the 2nd quarter. Ropes Wealth Advisors LLC now owns 1,006 shares of the medical research company’s stock worth $146,000 after buying an additional 656 shares during the period. 82.06% of the stock is currently owned by institutional investors and hedge funds.

About Edwards Lifesciences (NYSE:EW)

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

See Also: Do You Need a Fiduciary?

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.